Green Thumb Industries
Vertically integrated MSO operating in 15 markets. Known for premium brands (RYTHM, Dogwalkers, Beboe) and strong margins.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
CIN rates Green Thumb Industries Neutral with a 56 composite score and low conviction at 2/5. Fundamentals provide the principal support at 77, driven by strong operating-margin, gross-margin, market-capitalization and cash-runway subscores. The regulatory pillar contributes a middling 58: a favorable jurisdiction posture and no enforcement hits are offset by weak filing cadence. Market support remains limited at 40 because no quote was available through institutional pricing feeds. Editorial contribution is lowest at 30, reflecting no newsroom or brief activity in CIN newsroom coverage. The resulting profile supports neither an Overweight stance nor an Underweight call, leaving valuation confirmation and improved information flow as prerequisites for a more directional rating.
Licensed fundamentals data show year-over-year revenue growth of 7.4%, a solid but less powerful component than profitability. Gross margin stands at approximately 48.1%, while operating margin reaches about 13.6%; corresponding subscores of 80.2 and 87.4 anchor the fundamentals assessment. EBITDA of roughly $284.4 million and net income near $121.3 million reinforce the stable financial condition, while the positive-EBITDA cash-runway classification earns the pillar’s highest subscore at 90. Market capitalization of approximately $1.56 billion also supports the 87.7 size-tier subscore. Primary regulatory filings show the latest filing dated June 18, 2026, with four events during the prior 180 days but none during the latest 90 days. That lapse explains the 25 cadence subscore despite stronger jurisdiction and enforcement readings of 80 each.
The clearest forward catalyst is confirmation that the fundamentals pillar can retain its margin strength while improving the pace of growth. Another primary regulatory filing that preserves the current gross and operating margin profile, alongside revenue expansion above the present 7.4% rate, would reinforce earnings quality and create scope for the composite to move beyond Neutral. Better filing cadence would also improve visibility, but the rating remains anchored most directly to operating performance because fundamentals exceed every other pillar by at least 19 points. The single most important signal to watch is whether the next reported period delivers faster year-over-year revenue growth without sacrificing the 13.6% operating margin.
- Headquarters
- 325 WEST HURON STREET, SUITE 700, CHICAGO, IL, 60654
- Phone
- 312-471-6720
- Auditor
- as stated in their attestation report
- SEC CIK
- 1795139
- Website
- Company website
- Market cap
- $1.56B
- Enterprise value
- $1.77B
- P/E ratio
- 13.9
- PEG ratio
- 1.79
- Price to book
- 0.82
- Price to sales
- 1.30
- EV / EBITDA
- 3.48
- Revenue (TTM)
- $1.20B
- Gross profit (TTM)
- $575.3M
- EBITDA
- $284.4M
- Operating margin
- 13.6%
- Profit margin
- 10.1%
- Rev growth YoY
- 7.4%
- Return on equity
- 6.6%
- Return on assets
- 3.1%
- EPS (TTM)
- $0.51
- EPS est. current year
- $0.12
- Wall St. target price
- $15.67
- Shares outstanding
- 195.1M
- Insider ownership
- 1.9%
- Institutional ownership
- 8.2%
- Beta
- 0.93
- Full-time employees
- 4,900
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Proxy statement
- Latest DEF 14A
- Filing portal
- SEDAR+
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for Green Thumb Industries (GTBIF)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for Green Thumb Industries (GTBIF), a cannabis-sector equity listed on OTCMKTS in the US MSO category. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
Analyst average price target $21.38.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown, insider selling. (2 bullish signals, 3 bearish signals.)
Vertically integrated MSO operating in 15 markets. Known for premium brands (RYTHM, Dogwalkers, Beboe) and strong margins.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for GTBIF are maintained by Cannabis Investor News and refreshed throughout the trading day.